Academic and Employment Status in Patients With Generalized Myasthenia Gravis Treated With Eculizumab: A Case Series.

Q3 Medicine

Journal of Clinical Neuromuscular Disease Pub Date : 2022-06-01 DOI:10.1097/CND.0000000000000391

Seung Ah Kang, Megan Sweeney, Raghav Govindarajan

{"title":"Academic and Employment Status in Patients With Generalized Myasthenia Gravis Treated With Eculizumab: A Case Series.","authors":"Seung Ah Kang, Megan Sweeney, Raghav Govindarajan","doi":"10.1097/CND.0000000000000391","DOIUrl":null,"url":null,"abstract":"Objectives: To evaluate the impact of treatment with eculizumab, a terminal complement inhibitor, on academic and employment status in patients with refractory generalized myasthenia gravis (MG).Methods: Case review of 7 US patients.Results: Six patients were aged ≤65 years; one was a full-time student and the remainder were in employment before MG diagnosis. After diagnosis, all patients gave up work (n = 3) or reduced their study/working hours (n = 4). In the 12 months after eculizumab initiation, patients who had stopped work resumed working in some capacity, whereas those who had changed their work/study hours returned to their original work/study pattern. Patients also experienced a reduction in the number of MG exacerbations, and a clinically significant improvement in MG-Activities of Daily Living scores, and were able to reduce other MG medications.Conclusions: These results suggest that treatment with eculizumab may help maintain education/employment activity in patients with refractory generalized MG.","PeriodicalId":39645,"journal":{"name":"Journal of Clinical Neuromuscular Disease","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d9/e3/jcnd-23-210.PMC9126260.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Neuromuscular Disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/CND.0000000000000391","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 1

Abstract

Objectives: To evaluate the impact of treatment with eculizumab, a terminal complement inhibitor, on academic and employment status in patients with refractory generalized myasthenia gravis (MG).

Methods: Case review of 7 US patients.

Results: Six patients were aged ≤65 years; one was a full-time student and the remainder were in employment before MG diagnosis. After diagnosis, all patients gave up work (n = 3) or reduced their study/working hours (n = 4). In the 12 months after eculizumab initiation, patients who had stopped work resumed working in some capacity, whereas those who had changed their work/study hours returned to their original work/study pattern. Patients also experienced a reduction in the number of MG exacerbations, and a clinically significant improvement in MG-Activities of Daily Living scores, and were able to reduce other MG medications.

Conclusions: These results suggest that treatment with eculizumab may help maintain education/employment activity in patients with refractory generalized MG.

Abstract Image

查看原文本刊更多论文

Eculizumab治疗全身性重症肌无力患者的学业和就业状况:一个病例系列

目的:评估终末补体抑制剂eculizumab治疗对难治性全身性重症肌无力(MG)患者学业和就业状况的影响。方法:对美国7例患者的病例进行回顾性分析。结果:6例患者年龄≤65岁;其中一名是全日制学生，其余在MG诊断前有工作。诊断后，所有患者均放弃工作(n = 3)或减少学习/工作时间(n = 4)。在eculizumab启动后的12个月内，停止工作的患者恢复了一定的工作能力，而改变工作/学习时间的患者恢复了原来的工作/学习模式。患者还经历了MG发作次数的减少，MG-日常生活活动评分的临床显着改善，并且能够减少其他MG药物的使用。结论:这些结果表明，eculizumab治疗可能有助于维持难治性全身性MG患者的教育/就业活动。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Clinical Neuromuscular Disease Medicine-Medicine (all)

CiteScore

1.60

自引率

0.00%

发文量

期刊介绍： Journal of Clinical Neuromuscular Disease provides original articles of interest to physicians who treat patients with neuromuscular diseases, including disorders of the motor neuron, peripheral nerves, neuromuscular junction, muscle, and autonomic nervous system. Each issue highlights the most advanced and successful approaches to diagnosis, functional assessment, surgical intervention, pharmacologic treatment, rehabilitation, and more.